drugset / Trial / NCT01337089
Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Phase 3
Completed
660 enrolled
Jazz Pharmaceuticals
Otsuka Pharmaceutical Development & Commercialization, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This was a six-month open-label extension (OLE) study to evaluate the safety of long-term nabiximols (Sativex®) therapy when used as an adjunctive treatment in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding Phase 3 study and new (de novo) participants.
Timeline
- Start
- 2011-01-19
- Primary completion
- 2016-01-27
- Completion
- 2016-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nabiximols | Other / unclassified | 0.1 ml | Other |
Indications
No indication recorded.